Qureight
Revolutionizing drug development with AI-driven clinical insights.. [Contact for Pricing]
Last verified:
What is Qureight?
Qureight is a tech-first, AI-powered imaging CRO (Contract Research Organization) that accelerates clinical trials for lung and heart disease therapies. The company delivers enterprise-grade imaging and precision endpoints through a proprietary data and imaging curation platform that analyzes clinical imaging and healthcare data from patients with conditions like Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Hypertension, and Bronchiectasis.
The platform offers three core products: Global imaging CRO services with workflow tools for rapid site onboarding and patient evaluation in days rather than weeks; AI-powered endpoints and analytics including deep learning-based quantitative imaging models (Lung8™, Air8™, Fibr8™, Glass8™, and Vascul8™) that generate compartment-specific biomarkers from standard CT scans; and data science products including synthetic control arms created by integrating quantitative imaging with real-world clinical data from UK NHS and global data contracts.
Qureight is designed for biopharmaceutical companies, contract research organizations (CROs), and hospitals involved in drug development for lung and heart diseases. The company's AI-guided workflows and cloud-based technology enable faster analysis, helping customers streamline clinical trials, reduce development timelines, improve patient selection, and bring life-saving treatments to market faster.
The company was founded in 2018 by clinicians and researchers in Cambridge, UK, and has raised over $10M in funding. Qureight's world-leading team of scientists, engineers, and clinicians is based in Cambridge and London, and they partner with major pharmaceutical companies like AstraZeneca and Vicore Pharma.
Qureight pricing
Pricing model: Freemium
Qureight does not publish public pricing on its website. The company generates revenue through software licensing fees for platform access and additional rate-based fees for usage of specific tools. Pricing is enterprise-based and requires direct contact with the company ([email protected] or +44 1223 625384) for custom quotes. There is no free tier available. Services are offered as three core products that can be provided together or stand-alone: Global imaging CRO services, AI-powered endpoints and analytics, and Data science products including synthetic control arms.
Qureight pros
- AI-powered deep learning models for quantitative lung imaging biomarkers
- Proprietary Lung8™, Air8™, Fibr8™, Glass8™, and Vascul8™ biomarkers
- Rapid site onboarding - qualified imaging site in 2-3 weeks
- Patient evaluation in days instead of weeks through AI infrastructure
- Synthetic control arms using real-world data from UK NHS contracts
- End-to-end imaging CRO services under one platform
- Focus on therapeutic areas with high unmet need (IPF, PPF, PH, Bronchiectasis)
- Non-invasive alternative to invasive right heart catheterization for PH
- World's first digital biomarker for idiopathic pulmonary fibrosis
- Potentially halves clinical trial duration according to company claims
- GDPR, HIPAA, and 21 CFR Part 11 data security compliance
- Cloud-based platform for scalable, collaborative analysis
- Cohort enrichment and enrolled cohort reporting capabilities
- Integration of quantitative imaging with real-world clinical data
- Proven partnerships with AstraZeneca and Vicore Pharma
- 3D deep learning models that mirror lung physiology
- Image-based endpoints already used in global Phase 2 and 3 trials
Qureight cons
- Limited to lung and heart disease therapeutic areas only
- Enterprise-focused - not suitable for individual researchers or small practices
- Pricing not publicly disclosed - requires direct contact for quotes
- Requires CT scans as input - dependent on imaging infrastructure
- Synthetic control arms limited to diseases with sufficient real-world data
- No free tier available for testing or small-scale use
- Primarily serves biopharma and CROs, not academic researchers directly
- UK-based with limited geographic presence outside Europe
- Relatively young company founded in 2018 with limited long-term track record
Frequently asked questions about Qureight
What is Qureight?
Qureight is a tech-first, AI-powered imaging CRO (Contract Research Organization) that accelerates clinical trials for lung and heart disease therapies. The company provides enterprise-grade imaging and precision endpoints through a proprietary data and imaging curation platform that analyzes clinical imaging and healthcare data from patients with conditions like Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Hypertension, and Bronchiectasis.
What therapeutic areas does Qureight support?
Qureight provides focused support in clinical trials for therapeutic areas spanning lung and heart disease including Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Connective Tissue Disease-associated ILD (CTD-ILD), Pulmonary Hypertension (PH), Bronchiectasis, and Asthma.
What are Qureight's core products?
Qureight offers three main products that can be provided together or stand-alone: (1) Global imaging CRO services with workflow tools for rapid site onboarding, (2) AI-powered endpoints and analytics including deep learning-based quantitative imaging models (Lung8™, Air8™, Fibr8™, Glass8™, Vascul8™), and (3) Data science products including synthetic control arms, cohort enrichment, and enrolled cohort reporting.
What are Qureight's AI lung biomarkers?
Qureight's best-in-class proprietary lung image biomarkers include Lung8™, Air8™, Fibr8™, Glass8™, and Vascul8™. These were developed with 3D deep learning models to identify five key structural changes in the lung that indicate disease progression during clinical trials in response to drug treatment. These biomarkers are now being used as image-based endpoints in global Phase 2 and 3 clinical trials in IPF and Pulmonary Hypertension.
How do synthetic control arms work at Qureight?
Qureight's unique healthcare access through data contracts across the UK NHS and around the world has allowed them to build some of the largest datasets globally in diseases including Idiopathic Pulmonary Fibrosis, connective tissue diseases, and Pulmonary Hypertension. They use this data to build synthetic control arms that are carefully matched to existing drug or placebo trial arms, providing an ethical alternative to traditional placebo groups.
Who are Qureight's target customers?
Qureight's primary customers are biopharma companies, contract research organizations (CROs), and hospitals involved in drug development for lung and heart diseases. The company partners with major pharmaceutical companies including AstraZeneca and Vicore Pharma to accelerate clinical trials and bring treatments to market faster.
What makes Qureight different from traditional imaging CROs?
Qureight is a tech-first, AI-powered imaging CRO that uses proprietary AI and deep learning technology rather than traditional methods. Their platform accelerates patient inclusion through AI-driven study inclusion/exclusion decisions that rapidly onboard sites and evaluate patients in days instead of weeks. They also offer synthetic control arms and deep learning-based quantitative imaging biomarkers that traditional CROs don't provide.
Is Qureight data compliant with regulatory standards?
Yes, Qureight's software is data security compliant with GDPR, HIPAA, and 21 CFR Part 11, which are critical regulatory standards for clinical trial data management in pharmaceutical development.
How does Qureight help with Pulmonary Hypertension trials?
Qureight addresses the difficulty of monitoring Pulmonary Hypertension, which often relies on invasive right heart catheterization to directly measure pressures. Their AI-powered platform provides robust non-invasive ways to assess severity, stratify patients for trials, and detect treatment response over time through quantitative imaging biomarkers.
Where is Qureight based and who founded the company?
Qureight was founded in 2018 by clinicians and researchers in Cambridge, United Kingdom. The company is based in Cambridge and London, UK, with a world-leading team of scientists, engineers, and clinicians. Qureight has raised over $10M in funding including an $8.5 million Series A round.